Compare Enveric Biosciences Inc (ENVB) vs Prudential Financial Inc (PRU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Prudential Financial Inc — how do they compare? Enveric Biosciences Inc trades at $1.48 (market cap $6.80M), while Prudential Financial Inc trades at $113.01 (market cap $39.17B). The key difference: Prudential Financial Inc is far larger — about 5760.3× Enveric Biosciences Inc's market cap, and Prudential Financial Inc pays a 4.93% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Prudential Financial Inc for 145 Days on average.
| ENVB | PRU | |
|---|---|---|
Market Cap | $6.80M | $39.17B |
Volume | 64,867 | 1,436,917 |
Sector | Health | Financials |
52-Week High | $10.80 | $125.13 |
52-Week Low | $1.27 | $92.00 |
Typical Hold Time | 14 Days | 145 Days |
Enterprise Value | -$1.49M | $67.95B |
Dividend Yield | — | 4.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.45, down 3.01% on the day, with a bearish technical signal driven by moving averages. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten quarterly EPS expectations. Recent positive developments include a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in investor conferences.
The outlook is mixed; analyst consensus is 75% buy with strong earnings beats, but high negative ROE/ROA and operational cash burn pose significant risks. Investment opportunity hinges on successful drug development, while key risks include funding needs and clinical trial outcomes.
Prudential Financial (PRU) trades at $112.97, up 0.54% with a bearish technical signal despite recent earnings beats. The stock shows attractive valuation metrics with P/E of 10.29 and P/S of 0.61, while maintaining solid profitability with 6.04% net margin and 12.46% ROE. Recent strategic moves include the Alexforbes stake sale and rebranding to Prudential Wealth Advisors, reflecting focus on core operations.
While PRU offers value appeal through strong fundamentals and dividend yield, investors face headwinds from bearish technicals and mixed analyst sentiment. The company's capital rotation strategy and PGIM growth initiatives provide upside potential, but execution risks and market volatility remain concerns. Current price sits above consensus target of $105.67, suggesting limited near-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →
